The UltraCAR-T platform represents a significant advancement in cell therapy, specifically designed for the treatment of cancer. This segment focuses on the development and clinical evaluation of UltraCAR-T therapies, which utilize a novel approach to enhance the efficacy and safety of CAR-T cell treatments. Research and development activities include optimizing CAR-T cell design, manufacturing processes, and clinical trial protocols. The platform leverages advanced technologies such as the UltraVector platform to engineer immune cells with enhanced functional characteristics. The therapeutic areas covered are primarily oncology, with a focus on hematological malignancies and solid tumors. The patient impact is significant, as UltraCAR-T aims to provide more effective and durable responses compared to existing therapies, potentially improving overall survival and quality of life. Market positioning is based on providing a next-generation CAR-T therapy with improved safety and efficacy profiles. Future opportunities include expanding the platform to treat a broader range of cancers and developing combination therapies. Regulatory and clinical aspects involve rigorous clinical trials to demonstrate safety and efficacy, with the goal of obtaining FDA approval. Partnerships and collaborations are crucial for clinical trial execution and commercialization.

AdenoVerse Immunotherapy is a key business segment focused on developing innovative immunotherapies using a library of proprietary adenovectors for gene delivery. This segment's research and development efforts center on engineering adenovectors to deliver therapeutic genes directly to target cells, stimulating an immune response against diseases such as cancer and infectious diseases. The technologies employed include advanced adenovector engineering and gene delivery systems. Therapeutic areas include oncology, infectious diseases, and potentially other areas where immune modulation is beneficial. The patient impact is aimed at providing targeted and effective treatments with the potential for improved outcomes and reduced side effects. Market positioning is based on offering a unique gene delivery platform with the potential for enhanced efficacy and safety compared to traditional approaches. Future opportunities include expanding the platform to address a wider range of diseases and developing combination therapies. Regulatory and clinical aspects involve conducting clinical trials to demonstrate safety and efficacy, with the goal of obtaining regulatory approvals. Partnerships and collaborations are essential for clinical trial execution and commercialization.

The ActoBiotics platform focuses on the development of genetically modified bacteria (ActoBiotics) to deliver therapeutic proteins and peptides at mucosal sites. Research and development activities involve engineering food-grade bacteria, such as *Lactococcus lactis*, to produce and deliver therapeutic agents directly to the site of action. The platform utilizes advanced genetic engineering techniques to modify the bacteria and ensure targeted delivery. Therapeutic areas include mucosal diseases, inflammatory conditions, and potentially other areas where localized delivery of therapeutic agents is beneficial. The patient impact is aimed at providing targeted and effective treatments with reduced systemic exposure and improved patient outcomes. Market positioning is based on offering a unique platform for localized drug delivery with the potential for enhanced efficacy and safety. Future opportunities include expanding the platform to address a wider range of diseases and developing combination therapies. Regulatory and clinical aspects involve conducting clinical trials to demonstrate safety and efficacy, with the goal of obtaining regulatory approvals. Partnerships and collaborations are essential for clinical trial execution and commercialization.